Trial reportParasitology research2012
Vaccination of buffaloes with Fasciola gigantica recombinant glutathione S-transferase and fatty acid binding protein.
Trial report in Parasitology research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Th1 and Th2 cytokine gene expression in primary infection and vaccination against Fasciola gigantica in buffaloes by real-time PCR.Parasitology research · 2013Trial
- Exploring the functional and immunological diversity of the fatty acid-binding protein (FABP) family in Fasciola hepatica.Scientific reports · 2026Article
- Design of a Multi-Epitope Vaccine Based onInternational journal of molecular sciences · 2025Article
- Development of multi-epitope Cathepsin L driven short peptide vaccine againstFrontiers in veterinary science · 2025Article
- Combination Vaccines ofTropical medicine and infectious disease · 2023Article
- The 22nd Chromatography Component of theAnimals : an open access journal from MDPI · 2023Article
- Article
- Fasciolosis: pathogenesis, host-parasite interactions, and implication in vaccine development.Frontiers in veterinary science · 2023Review
- Secondary infection ofFrontiers in veterinary science · 2023Article
- Assessment of Fasciola hepatica glutathione S-transferase as an antigen for serodiagnosis of human chronic fascioliasis.Acta tropica · 2018Article
- Fasciola and fasciolosis in ruminants in Europe: Identifying research needs.Transboundary and emerging diseases · 2018Review
- Physio-biochemical parameters: a potential tool for target-selective treatment of haemonchosis in the small ruminants.Tropical animal health and production · 2017Article
- Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults.PLoS neglected tropical diseases · 2017Article
- Transcriptomic responses of water buffalo liver to infection with the digenetic fluke Fasciola gigantica.Parasites & vectors · 2017Article
- Juvenile-specific cathepsin proteases in Fasciola spp.: their characteristics and vaccine efficacies.Parasitology research · 2015Review
- Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant.Frontiers in immunology · 2015Review
- Cloning and characterization of the fatty acid-binding protein gene from the protoscolex of Taenia multiceps.Parasitology research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fasciola gigantica, causative agent of tropical fasciolosis, inflicts substantial economic losses on the livestock industry, affecting severely buffalo productivity in the tropical countries. Very few vaccination trials with different target antigens against F. gigantica infection have been conducted in this host. Present study describes a vaccination trial in buffaloes with F. gigantica recombinant glutathione S-transferase and fatty acid binding protein. The two recombinant proteins were expressed in Escherichia coli and evaluated for their immunoprophylactic potential in buffalo calves, using montanide 70 M-VG, a mineral oil-based adjuvant, for delivering the antigens. Buffalo calves were distributed in three groups, with group I, II and III calves immunized with recombinant glutathione S-transferase, fatty acid binding protein and a cocktail of these two antigens, respectively. Immunization of the calves evoked a mixed IgG1 and IgG2 antibody response. Present vaccination trial in these animals achieved a maximum protection level of 35%, when the two antigens were used in combination. Eosinophils were measured in both immunized and non-immunized challenge control animals, which showed a steady increase in their count in response to immunization with both the antigens and infection with F. gigantica, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.